Symptomatic COVID-19 Infection Laboratory-Confirmed
14
2
3
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
21.4%
3 terminated out of 14 trials
57.1%
-29.4% vs benchmark
7%
1 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Tocilizumab for Patients With Cancer and COVID-19 Disease
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
Dasatinib for the Treatment of Moderate and Severe COVID-19
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year